Difference between revisions of "Rilzabrutinib (PRN-1008)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - " (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT[0-9]{8})" to " [$1 Clinical Trials Registry]") |
Warner-admin (talk | contribs) m (Text replacement - "(NCT[0-9]{8}) Clinical Trials Registry" to "$1 $1") |
||
(One intermediate revision by the same user not shown) | |||
Line 6: | Line 6: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Immune thrombocytopenia]]=== | ===[[Immune thrombocytopenia]]=== | ||
− | #'''PRN1008-010:''' Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 2022 Apr 14;386(15):1421-1431. [https://doi.org/10.1056/nejmoa2110297 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35417637/ PubMed] [https://clinicaltrials.gov/ | + | #'''PRN1008-010:''' Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 2022 Apr 14;386(15):1421-1431. [https://doi.org/10.1056/nejmoa2110297 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35417637/ PubMed] [https://clinicaltrials.gov/study/NCT03395210 NCT03395210] |
==Also known as== | ==Also known as== |
Latest revision as of 21:38, 4 July 2023
General information
Class/mechanism: BTK inhibitor
Route: PO
Extravasation: n/a
Preliminary data
Immune thrombocytopenia
- PRN1008-010: Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 2022 Apr 14;386(15):1421-1431. link to original article PubMed NCT03395210
Also known as
- Code name: PRN-1008